Company intelligence / Profile preview

Fount Bio

Cambridge, Massachusetts, United Statesfountbio.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Developed the world's first platform of products that build crosslinked hyaluronic acid within living tissues; won Innovation of the Year at 2024 IMCAS

Therapeutic areas: Dermatology
Modalities: Glycopolymer-based productsBiopolymer-based products
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Flī-HA

Pre-clinical

Indications: Tissue rejuvenation

Beyond the preview

Go deeper on Fount Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fount Bio.

Explore the full profile